Silence Therapeutics plc (SLN) Key Metrics
SLN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $539.5M
- Enterprise value
- $673.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 877.2
- Price / book
- 18.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.45
SLN key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSLN valuation Price multiples at each fiscal year-end price.
SLN returns How much profit the business earns on the capital it uses.
SLN per-share figures Results divided by the shares outstanding at year-end.
SLN financial health Debt, liquidity and how easily interest is covered.
SLN efficiency & capital use Working capital cycle and where the cash goes.
SLN valuation history
SLN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SLN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SLN price vs earnings per share
SLN key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Valuation | ||
| Market capitalization | $95.7M | $106.1M |
| Enterprise value | $10.8M | −$11.5M |
| Price / sales | 171.2 | 2.5 |
| Price / book | 1.5 | 1.0 |
| EV / sales | 19.3 | -0.3 |
| Earnings yield | −92.6% | −42.7% |
| Free cash flow yield | −65.1% | −51.1% |
| Share price at fiscal year-end | $6.08 | $6.88 |
| Per share | ||
| Revenue per share | $0.04 | $2.81 |
| Earnings per share | −$5.63 | −$2.94 |
| Operating cash flow per share | −$3.96 | −$3.51 |
| Free cash flow per share | −$3.96 | −$3.52 |
| Cash per share | $5.41 | $7.63 |
| Book value per share | $3.96 | $6.94 |
| Tangible book value per share | $3.26 | $6.44 |
| Capex per share | $0.00 | $0.01 |
| Debt per share | $0.01 | $0.01 |
| Shares outstanding | 15.7M | 15.4M |
| Change in shares outstanding | +2.1% | — |
| Returns & profitability | ||
| Return on equity (ROE) | −104.6% | −42.3% |
| Return on assets (ROA) | −60.4% | −28.0% |
| Return on tangible assets | −73.5% | −29.4% |
| Free cash flow margin | — | −125.3% |
| Financial health | ||
| Total debt | $160,000 | $93,452 |
| Cash & short-term investments | $85.1M | $117.7M |
| Net debt | −$85.0M | −$117.6M |
| Debt / equity | 0.00 | 0.00 |
| Debt / assets | 0.00 | 0.00 |
| Current ratio | 8.72 | 11.14 |
| Quick ratio | 8.72 | 11.14 |
| Working capital | $105.0M | $136.2M |
| Invested capital | −$22.6M | −$10.5M |
| Tangible asset value | $51.4M | $99.3M |
| Net current asset value | $49.5M | $94.9M |
| Graham net-net per share | $2.19 | $4.12 |
| Capital allocation | ||
| Capex / revenue | 9.8% | 0.4% |
| Capex / depreciation | 0.10 | 0.36 |
| Stock-based compensation / revenue | 1,444.4% | 24.1% |
| R&D / revenue | 12,120.4% | 156.9% |
| SG&A / revenue | 3,997.1% | 62.1% |
| Efficiency | ||
| Days sales outstanding | 8,289.3 | 6.6 |
| Days payables outstanding | 6,249.1 | 91.3 |
| Cash conversion cycle (days) | 2,040.3 | -84.7 |
| Receivables turnover | 0.04 | 55.72 |
| Payables turnover | 0.06 | 4.00 |
| Asset turnover | 0.00 | 0.27 |
| Average receivables | $12.7M | $776,375 |
| Average payables | $3.7M | $3.0M |
| Intangibles / total assets | 8.3% | 4.8% |
Computed from SLN's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SLN valuation and financial ratios
Silence Therapeutics earned a return on equity of −104.6% in fiscal 2025. It ended the year with $0.2 million of debt and $85.1 million in cash and short-term investments, a net cash position of $85.0 million.
See the SLN income statement, the SLN chart for price history, or the SLN stock overview for the latest quote and news.
SLN key metrics FAQ
What is Silence Therapeutics's return on equity?
Silence Therapeutics's return on equity (ROE) was −104.6% in fiscal 2025: net income of -$88.6 million on average shareholders' equity of $84.7 million.
How much debt does Silence Therapeutics have?
Silence Therapeutics had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Silence Therapeutics's free cash flow yield?
Silence Therapeutics generated -$62.3 million of free cash flow in fiscal 2025, a free cash flow yield of −65.1% on its market value at year-end ($95.7 million).
What is Silence Therapeutics's current ratio?
Silence Therapeutics's current ratio was 8.72 at the end of fiscal 2025: current assets were 8.72 times current liabilities.